ISONIAZID

First approved in 1952

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H7N3O
Molecular Weight	137.1393
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NNC(=O)C1=CC=NC=C1

InChI

InChIKey=QRXWMOHMRWLFEY-UHFFFAOYSA-N

InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)

HIDE SMILES / InChI

Molecular Formula	C6H7N3O
Molecular Weight	137.1393
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1553312b-ed76-421c-a055-2579bdcf366c#i4i_indications_id_indications
Curator's Comment: Description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00951 http://www.rxlist.com/isoniazid-drug.htm

Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically M. tuberculosis, M. bovis and M. kansasii. Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. Isoniazid is a prodrug and must be activated by bacterial catalase. Isoniazid inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor. The most frequent adverse reactions to isoniazid are those affecting the nervous system and the liver.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Enoyl-[acyl-carrier-protein] reductase 5 Target ID: CHEMBL1849 Sources: http://www.drugbank.ca/drugs/DB00951	Binding Agent 1076		0.75 nM [Ki]
Catalase-peroxidase 3 Target ID: P9WIE4\|\|\|Q50553 Gene ID: NA Gene Symbol: katG Target Organism: Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh) Sources: http://www.drugbank.ca/drugs/DB00951	Substrate 661

Conditions

Condition	Modality	Targets	Highest Phase	Product
Tuberculosis 83 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1553312b-ed76-421c-a055-2579bdcf366c	Curative		Approved 8583	Isoniazid Approved Use all forms of tuberculos in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Also is recommended as preventive therapy Launch Date 1970

C_max

Value	Dose	Analyte	Population
2.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
16.6 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
9.71 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
37.81 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.06 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
71.52 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.96 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
53.17 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
86% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29735566/	unknown, unknown		ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: https://pubmed.ncbi.nlm.nih.gov/1257824	healthy, 16 Health Status: healthy Age Group: 16 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1257824	Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea Vomiting Grand mal seizure Lethargy Coma Sources: https://pubmed.ncbi.nlm.nih.gov/1257824
20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: https://pubmed.ncbi.nlm.nih.gov/1257824	healthy, 16 Health Status: healthy Age Group: 16 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1257824	Disc. AE: Nystagmus, Hyperreflexia... AEs leading to discontinuation/dose reduction: Nystagmus Hyperreflexia Sources: https://pubmed.ncbi.nlm.nih.gov/1257824
112 mg/kg single, oral Overdose Dose: 112 mg/kg Route: oral Route: single Dose: 112 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/9490997	unhealthy, 17 Health Status: unhealthy Age Group: 17 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/9490997	Disc. AE: Lethargy, Seizures... AEs leading to discontinuation/dose reduction: Lethargy Seizures Coma Tachycardia Sources: https://pubmed.ncbi.nlm.nih.gov/9490997
25 g single, oral Overdose Dose: 25 g Route: oral Route: single Dose: 25 g Sources: https://pubmed.ncbi.nlm.nih.gov/25779481	healthy, 20 Health Status: healthy Age Group: 20 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/25779481	Disc. AE: Generalized tonic-clonic seizure... AEs leading to discontinuation/dose reduction: Generalized tonic-clonic seizure Sources: https://pubmed.ncbi.nlm.nih.gov/25779481
900 mg 1 times / week multiple, oral Recommended Dose: 900 mg, 1 times / week Route: oral Route: multiple Dose: 900 mg, 1 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/22150035	unhealthy, 25–47 Health Status: unhealthy Age Group: 25–47 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22150035	Disc. AE: Hepatotoxicity, Hypersensitivity... AEs leading to discontinuation/dose reduction: Hepatotoxicity (0.3%) Hypersensitivity (2.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/22150035
3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3337420	healthy, 7 Health Status: healthy Age Group: 7 Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3337420	Disc. AE: Seizures, Metabolic acidosis... AEs leading to discontinuation/dose reduction: Seizures (severe) Metabolic acidosis Coma Oliguria Sources: https://pubmed.ncbi.nlm.nih.gov/3337420
900 mg 3 times / week multiple, oral Recommended Dose: 900 mg, 3 times / week Route: oral Route: multiple Dose: 900 mg, 3 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf	Disc. AE: Hepatitis... AEs leading to discontinuation/dose reduction: Hepatitis (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP3A 227 CYP2E1 1060 CYP1A2 2153 CYP2A6 879		CYP2E1 131

Drug as perpetrator

Target	Modality	Activity
CYP2C9 2497	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki 102 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki 110 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki 126 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki 13 uM]
CYP3A 317	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki 51.8 uM]
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11868802/	yes [Ki 60 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki >1000 uM]
CYP2E1 1146	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/8354023/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY445177	https://www.001chemical.com/chem/54-85-3
3B Scientific (Wuhan) Corp	3B1-00315	http://www.3bsc.com/index/pro_info.php?id=20527
3B Scientific (Wuhan) Corp	3B3-029741	http://www.3bsc.com/index/pro_info.php?id=50998
AA Blocks	AA00I9KA	http://www.aablocks.com/goods/Goods/detail?id=AA00I9KA
Aaron Chemicals	AR00IAC2	http://www.aaronchem.com/54-85-3
abcr GmbH	AB117136	http://www.abcr.com/shop/en/AB117136
AbMole Bioscience	M5713	http://www.abmole.com/products/isoniazid.html
Acadechem	ACDS-026244	http://www.acadechemical.com/product/100943
Accela ChemBio Inc	SY010614	http://www.accelachem.com/cn/search.html?keyword=SY010614&attname=GoodsCode
Achemica	ACMC-209ljq	http://www.achemica.com/prodinfo/?id=128880
Achemo Scientific Limited	AC-65231	http://www.achemo.com/search/?Keyword=54-85-3
Achemtek	0102-025873	http://www.achemtek.com/54-85-3
Acros Organics	AC122600050	https://www.fishersci.com/shop/products/isonicotinic-acid-hydrazide-99-acros-organics/AC122600050
Acros Organics	AC122601000	https://www.fishersci.com/shop/products/isonicotinic-acid-hydrazide-99-acros-organics/AC122601000
Acros Organics	AC122605000	https://www.fishersci.com/shop/products/isonicotinic-acid-hydrazide-99-acros-organics/AC122605000
AEchem Scientific Corp., USA	AE065418	https://www.aechemsc.com/info_products/AE065418.php
AHH Chemical co.,ltd	MT-16053	http://www.ahhchemical.com/product/MT-16053.html
AK Scientific, Inc. (AKSCI)	65478	http://www.aksci.com/item_detail.php?cat=65478
Alfa Aesar	A10583	https://www.alfa.com/en/catalog/A10583/
Alfa Chemistry	AP54853-A	https://reagents.alfa-chemistry.com/product/isoniazid-cas-54-85-3-12958.html
Alfa Chemistry	AP54853-B	https://reagents.alfa-chemistry.com/product/isoniazid-cas-54-85-3-12959.html
Alichem	29206165	http://www.alichem.com/en/products/54-85-3.html
Alsachim	820	http://www.alsachim.com/product-C3287-glo.bal-view.html
Angene	AGN-PC-04X6J8	http://www.angenechemical.com/productshow/AGN-PC-04X6J8.html
Anward	ANW-32196	http://www.anward.com/pro_result/24734
ApexBio Technology	B1957	http://www.apexbt.com/isoniazid.html
Ark Pharm	AK-46317	http://www.arkpharminc.com/products/54-85-3.html
Aronis	ARONIS25141	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=18034
Aurora Fine Chemicals LLC	A00.156.063	http://online.aurorafinechemicals.com/info?ID=A00.156.063
Aurum Pharmatech LLC	T7976	http://www.Aurumpharmatech.com/Product/ProductDetails/T7976
Avantor Inc	200012-850	https://us.vwr.com/store/product/7514538/isoniazid
BioChemPartner	BCP13791	http://www.biochempartner.com/54-85-3-BCP13791
BioCrick	BCC9003	http://www.biocrick.com/Isoniazid-BCC9003.html
BLD Pharm	BD21389	http://www.bldpharm.com/products/54-85-3.html
BOC Sciences	774596-24-6	https://www.bocsci.com/isoniazid-d4-cas-774596-24-6-item-133736.html
Boerchem	BC204682	http://www.boerchem.com/?product_40616.html
Chem Scene	CS-2371	http://www.chemscene.com/54-85-3.html
Chemenu	CM110204	http://www.chemenu.com/products/CM110204
ChemMol	44001914	http://www.chemmol.com/chemmol/44001914.html
ChemMol	49417216	http://www.chemmol.com/chemmol/49417216.html
ChemMol	99102376	http://www.chemmol.com/chemmol/99102376.html
Chemspace	CSSB00000189768	https://chem-space.com/CSSB00000189768
Clearsynth	CS-O-10901	https://www.clearsynth.com/en/CSO10901.html
CSNpharm	CSN12770	https://www.csnpharm.com/products/isonicotinic-acid-hydrazide.html
DC Chemicals	DCAPI1242	http://www.dcchemicals.com//product_show-Isoniazid_Tubizid_.html
Enamine	Z58981801	https://www.enaminestore.com/catalog/Z58981801
eNovation Chemicals	D386801	http://www.enovationchem.com/productDetails.asp?productID=D386801
eNovation Chemicals	D589900	http://www.enovationchem.com/productDetails.asp?productID=D589900
Finetech	FT-0627424	http://www.finetechnology-ind.com/prod/detail/pub/54-85-3.html
Finetech	FT-0670476	http://www.finetechnology-ind.com/prod/detail/pub/774596-24-6.html
Glentham Life Sciences	GA2329	http://www.glentham.com/products/product/GA2329/
Hairui	HR135335	http://www.hairuichem.com/en/product/54-85-3.html
iChemical	EBD955	http://www.ichemical.com/products/54-85-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00221458	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00221458
LGC Standards	MM1529.00-0250	https://www.lgcstandards.com/US/en/p/MM1529.00-0250
Matrix Scientific	127307	https://www.matrixscientific.com/127307.html
mcule	MCULE-6324947959	https://mcule.com/MCULE-6324947959/
MedChem Express	HY-B0329	https://www.medchemexpress.com/Isoniazid.html
Molcore	MC445177	https://www.molcore.com/product/54-85-3
Oakwood	236758	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=117757&ExtHyperLink=1
Parchem	29182	http://www.parchem.com/chemical-supplier-distributor/Isoniazide-019182.aspx
Renno Tech	RP01120	http://www.rennotech.com/product_show.asp?id=7507
Sigma-Aldrich	1349706_USP	https://www.sigmaaldrich.com/catalog/product/usp/1349706?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	75182_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/75182?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	I0500000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/i0500000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	I3377_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/i3377?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	PHR1932_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/phr1932?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S010587	http://www.sinfoobiotech.com/product/1013985
Smolecule	S530930	http://www.smolecule.com/products/s530930
TCI (Tokyo Chemical Industry)	I0138	http://www.tcichemicals.com/eshop/en/us/commodity/I0138/index.html
THE BioTek	bt-272339	https://www.thebiotek.com/product/inhibitors/bt-272339
VladaChem	VL142924	https://www.vladachem.com/product.php?products=54-85-3
VladaChem	VL163436	https://www.vladachem.com/product.php?products=54-85-3
VladaChem	VL268039-100G	https://www.vladachem.com/product.php?products=54-85-3

PubMed

Title	Date	PubMed
Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids. 2.	2001-05-10	11334565
Isoniazid-induced beta-hydroxybutyric acidosis.	2001-05-01	11329248
Efficacy of chemotherapy for prostatic tuberculosis-a clinical and histologic follow-up study.	2001-05	11337284
Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.	2001-05	11337231
Substandard tuberculosis drugs on the global market and their simple detection.	2001-05	11336276
Influence of endothelium in dose-dependent inhibition and potentiation by isoniazid of isosorbide dinitrate relaxation of rat aorta.	2001-05	11336113
Ion interaction reagent reversed-phase high-performance liquid chromatography determination of anti-tuberculosis drugs and metabolites in biological fluids.	2001-04-25	11339291
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.	2001-04-20	11330495
A whole blood bactericidal assay for tuberculosis.	2001-04-15	11262217
On-column amperometric detection of ofloxacin and pasiniazid in urine by capillary electrophoresis with an improved fractured joint and small detection cell.	2001-04	11340975
Higher activity of morphazinamide over pyrazinamide against intracellular.	2001-04	11334260
Utility of PCR assays for rapid diagnosis of BCG infection in children.	2001-04	11334259
Heteroresistance in Mycobacterium tuberculosis.	2001-04	11334252
Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases.	2001-04	11334251
A clinic-based molecular epidemiologic study of tuberculosis in Monterrey, Mexico.	2001-04	11334249
[Resistant tuberculosis in Denmark].	2001-03-26	11293312
The uses of error: iatrogenic hepatitis.	2001-03-10	11253985
Active site structure of the catalase-peroxidases from Mycobacterium tuberculosis and Escherichia coli by extended X-ray absorption fine structure analysis.	2001-03-09	11257507
Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan.	2001-03-03	11247549
Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan.	2001-03	11326827
Survey for tuberculosis in a tribal population in North Arcot District.	2001-03	11326823
[Central nervous system tuberculosis in children: 2. Treatment and outcome].	2001-03	11299436
Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines.	2001-03	11282269
Mycobacterial FurA is a negative regulator of catalase-peroxidase gene katG.	2001-03	11251835
Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates.	2001-03	11243965
Arylamine N-acetyltransferases - of mice, men and microorganisms.	2001-03	11239577
Antimycobacterial in vitro activity of cobalt(II) isonicotinoylhydrazone complexes. Part 10.	2001-02-12	11212096
[Diagnosis and treatment of tuberculosis in Spain: results of the Multicenter Project for Tuberculosis Research].	2001-02-10	11222172
[Disseminated disease by Mycobacterium kansasii resistant to isoniazid and rifampin in patients] with AIDS].	2001-02	11333577
[Bronchiolo-alveolar cell carcinoma arising after active pulmonary tuberculosis' report of two cases].	2001-02	11321828
Connatal tuberculosis in an extremely low birth weight infant: case report and management of exposure to tuberculosis in a neonatal intensive care unit.	2001-02	11271396
Low failure rate in standardised retreatment of tuberculosis in Nicaragua: patient category, drug resistance and survival of 'chronic' patients.	2001-02	11258506
TB prevention in HIV clinics in New York City.	2001-02	11258505
Surgical management of multidrug-resistant tuberculosis.	2001-02	11257774
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.	2001-01-26	11216930
[Two children with extrapulmonary symptoms due to tuberculosis].	2001-01-20	11206119
Risk factors for hepatotoxicity during anti-tuberculosis chemotherapy in Asian populations.	2001-01	11263525
The management of anti-tuberculosis drug-induced hepatotoxicity.	2001-01	11263519
Outbreak of multidrug-resistant tuberculosis at a methadone treatment program.	2001-01	11263518
Drug-resistant tuberculosis in foreign-born persons from Mexico, the Philippines, and Vietnam-United States, 1993-1997.	2001-01	11263517
Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy.	2001-01	11263515
Prevalence of drug-resistant tuberculosis in an HIV endemic area in northern Thailand.	2001-01	11263513
Tuberculosis treatment: dangerous regimens?	2001-01	11263509
Does tuberculosis after kidney transplantation follow the trend of tuberculosis in general population?	2001-01	11256535
[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?].	2001-01	11256251
Comparison of two rapid colorimetric methods for determining resistance of mycobacterium tuberculosis to rifampin, isoniazid, and streptomycin in liquid medium.	2001-01	11245320
Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started?	2001-01	11243745
[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].	2001-01	11211781
The role of fluoroquinolones in tuberculosis today.	2001	11217874
Isoniazid-associated hepatitis--serum enzyme determinations and histologic features.	1975-05	1130028

Patents

Sample Use Guides

In Vivo Use Guide

Adults: 5 mg/kg up to 300 mg daily in a single dose; or 15 mg/kg up to 900 mg/day, two or three times/week Children: 10 mg/kg to15 mg/kg up to 300 mg daily in a single dose; or 20 mg/kg to 40 mg/kg up to 900 mg/day, two or three times/week

Route of Administration: Oral

In Vitro Use Guide

1.56 μg/ml

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:47:42 GMT 2025` Edited by `admin` on `Mon Mar 31 17:47:42 GMT 2025`
Record UNII	V83O1VOZ8L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Isonicotinic acid hydrazide

Preferred Name

English

ISONIAZID

Official Name

English

HYDRAZID

Common Name

English

ISOBICINA

Common Name

English

ERALON

Common Name

English

4-PYRIDINECARBOXYLIC ACID, HYDRAZIDE

Common Name

English

INH

Brand Name

English

STANOZIDE

Brand Name

English

ISONIAZID [USP MONOGRAPH]

Common Name

English

HYZYD

Brand Name

English

MYBASAN

Common Name

English

NYDRAZID

Brand Name

English

4-PYRIDINECARBOXYLIC ACID HYDRAZIDE [WHO-IP]

Common Name

English

CEDIN

Common Name

English

ISONIAZID [ORANGE BOOK]

Common Name

English

ATCOTIBINE

Common Name

English

ISONIAZID [JAN]

Common Name

English

COTINAZIN

Common Name

English

RIMIFON

Brand Name

English

DITUBIN

Common Name

English

ARMAZID

Common Name

English

NEUMANDIN

Common Name

English

IPCAZIDE

Common Name

English

TEEBACONIN

Common Name

English

ISONIAZID [EP MONOGRAPH]

Common Name

English

ISONICOTINIC ACID HYDRAZIDE [WHO-IP]

Common Name

English

ISONIAZID [USP-RS]

Common Name

English

HIDRASONIL

Common Name

English

ISONIAZID [WHO-IP]

Common Name

English

ISONIAZID [EP IMPURITY]

Common Name

English

DINACRIN

Common Name

English

ISONIAZID [MI]

Common Name

English

isoniazid [INN]

Common Name

English

RIFAMATE COMPONENT ISONIAZID

Common Name

English

ISONIAZID [MART.]

Common Name

English

ARMAZIDE

Common Name

English

NSC-9659

Code

English

ERTUBAN

Common Name

English

ISONIAZIDUM [WHO-IP LATIN]

Common Name

English

RIFATER COMPONENT ISONIAZID

Common Name

English

ISONICOTINYLHYDRAZINE

Systematic Name

English

Isoniazid [WHO-DD]

Common Name

English

TISIODRAZIDA

Common Name

English

DIANICOTYL

Common Name

English

DOW-ISONIAZID

Brand Name

English

ISONICOTINIC ACID HYDRAZIDE [IARC]

Common Name

English

ISONIAZID [HSDB]

Common Name

English

ISONICOTAN

Common Name

English

ISCOTIN

Brand Name

English

ISONIAZID [VANDF]

Common Name

English

ISIDRINA

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175483